JIP
DFTX

Jaffetilchin Investment Partners’s Definium Therapeutics DFTX Stock Holding History

Jaffetilchin Investment Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,389
Closed -$13.6K – 919
2024
Q3 		$13.6K Buy
+2,389
New +$16.6K ﹤0.01% 844
2022
Q3 		– Sell
-2,457
Closed -$24K – 334
2022
Q2 		$24K Buy
+2,457
New +$31.1K ﹤0.01% 322
2022
Q1 		– Sell
-2,457
Closed -$51K – 361
2021
Q4 		$51K Hold
2,457
– – ﹤0.01% 342
2021
Q3 		$89K Sell
2,457
-48
-2% -$2.08K 0.01% 356
2021
Q2 		$131K Buy
+2,505
New +$131K 0.01% 362

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jaffetilchin Investment Partners's DFTX Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Definium Therapeutics (DFTX) in Q4 2024, closing a stake of 2,389 shares — an estimated $13.6K sold.

Jaffetilchin Investment Partners first reported a position in DFTX in Q2 2021 and held it in 5 quarters. The position peaked at $131K in Q2 2021. 172 funds tracked by Wall St. Rank hold DFTX as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Definium Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 2,389 Definium Therapeutics shares in Q4 2024, an estimated $13.6K.
  • Jaffetilchin Investment Partners first reported a position in Definium Therapeutics in Q2 2021 and held it in 5 quarters.
  • Jaffetilchin Investment Partners's Definium Therapeutics position peaked at $131K in Q2 2021.
  • 172 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.